Verastem Oncology VSTM presented COPIKTRA data showing response rates of 44% to 57%, including complete response rates of 15% to 22% in patients with relapsed or refractory peripheral T-cell lymphoma.
Verastem is a biopharmaceutical company focused on developing medicines to improve the survival and quality of life of cancer patients. COPIKTRA is also being developed by for the treatment of peripheral T-cell lymphoma.
“Although the patient numbers are small in these two Phase 1 studies, we see a positive trend in response rates,” said Steven Horwitz, Memorial Sloan Kettering Cancer Center, co-principal investigator of the Phase 1 and 2 studies, and lead author of the oral presentation.
Verastem shares traded higher by 2.5% at $1.63 in Friday's pre-market session.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.